Skip to main content
OpenTrials
Completed

NCT Number: NCT04954807

Indonesia After Discharge LBW Infant HMF Supplementation Study

Low birth weight (LBW) infant (1800-2449 gram) will be given the new human milk fortifier (HMF) which contains protein, lipid, carbohydrate and micronutrients after discharge. Human Milk Fortifier or placebo (carbohydrate only with similar calorie content) will be provided until 3 months of age. The investigators want to evaluate if the addition of HMF to mother's milk while breastfeeding LBW infants after discharge influences growth and body composition up to 3 months of age.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 day–14 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Budi Kemuliaan Hospital, Jakarta, Central Jakarta, Indonesia

Loading trial locations.

About this study

This is a prospective two arms parallel double-blind randomized clinical trial in LBW infants. Clinically healthy LBW infants discharge on oral feeding of human milk before 2 weeks of age (< 15 days old) will be invited to participate in the study. Exclusively or predominantly breastfed infants will be encourage to use finger feeding as method of supplementation, but mothers can choose their own preferences if they wish to do so.

After signing the informed consent by parent, subject will be randomized to one of four group. Randomization list were prepare by one investigator who do not involve in recruitment, outcome measures and statistical analysis. Study product will be labeled as A, B, C D in similar tin. Only manufacturer know the content of these tins and the code will be revealed after statistical analysis completed. Parents will be given this 200 g tin of study product and ask to return the tin after 14 days of opening. Unblinded assistant will weight the tin before and after opening to estimate the HMF intake for 14 days.

This study will be conducted in several hospitals in Greater Jakarta.

Adherence to study protocol will be encouraged during face to face session initially in dispensing study product and subsequent visits (visit 1 at one-month-old, visit 2 at two months old). These sessions will include the reminder of the importance of following study protocol, breastfeeding support if needed and discussion about difficulties that arise. The investigators will also remind mothers via text to fill in three days diary of intake one week before each visit.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Low birth weight infants (1800-2499 g) with oral feeding
  • Exclusively breastfed or predominantly breastfed (consuming term infant formula less than 50 ml/Kg BW/day) at discharge
  • Discharge from the hospital before 2 weeks of age and maximal age of enrolment is 14 days old
  • Live in greater Jakarta
  • Parents agree in writing to study participation and indicate their intention to follow study procedures.

Exclusion criteria

Any subject who has major congenital anomaly or any other disorder(s) that infers with normal feeding, growth, and neurodevelopment.

Participating in another intervention trial

Treatment and study plan

human milk fortified

Dietary Supplement

HMF will be given 6 scoops a day

Placebo

Dietary Supplement

Placebo will be given six scoops a day

Primary outcomes

  1. Gaining weight

    Time frame: three months of age

    Gain in weight (g/kg initial weight & difference) between study enrolment and three months of age

Secondary outcomes

  1. Average weight gain

    Time frame: enrollment to three months of age

    Average daily weight gain (g/kg/day) from enrolment to at three months of age

  2. Gaining length

    Time frame: Three months of age

    Gain in length (mm initial length & difference) from study enrolment to the age of 3 months

  3. Head circumference

    Time frame: Three months of age

    Gain in head circumference (mm initial head circumference & difference) from study enrolment to the age of 3 months

  4. Weight for age

    Time frame: Three months of age

    Difference of weight for age (Z score) from study enrolment to the age of 3 months

  5. Body fat percentage

    Time frame: Three months of age

    Difference in body fat percentage between groups

  6. Stool consistency

    Time frame: enrollment to three months of age

    Median type of stools according to Diapered Infant stool chart between groups

  7. Stool frequency

    Time frame: enrollment to three months of age

    average stool frequency per day between groups

  8. Vomit

    Time frame: enrollment to three months of age

    Number of subjects who reported to have vomit between groups

  9. Bloating

    Time frame: enrollment to three months of age

    Number of subjects who reported to experience bloating between groups

  10. Fever

    Time frame: enrollment to three months of age

    Number of subjects who reported to experience fever between groups

  11. Rehospitalization

    Time frame: enrollment to three months of age

    Number of subjects who reported being hospitalized between groups

Sponsors and collaborators

Lead sponsor

Indonesia University

Other

Collaborators

  • Ludwig-Maximilians - University of Munich

Registry information

Official study title

Growth and Body Composition of Low Birth Weight Infants Supplemented With Human Milk Fortifier After Discharge: A Double-Blind Randomized Clinical Trial

Acronym: DAHLIA

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Jul 8, 2021
Registry last updated
Mar 7, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.